Rat model for dual opportunistic pathogen prophylaxis: Cryptosporidium parvum and Pneumocystis carinii.
Oz
H S
HS
Department of Infectious Diseases and Comparative Medicine Division, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, USA.
Hughes
W T
WT
Rehg
J E
JE
D000818:Animals; D002219:Carbamates / Q000627:therapeutic use*; D003457:Cryptosporidiosis / Q000150:complications / Q000188:drug therapy* / Q000517:prevention & control; D016785:Cryptosporidium parvum / Q000472:pathogenicity; D003907:Dexamethasone / Q000494:pharmacology; D004195:Disease Models, Animal; D005260:Female; D007082:Ileum / Q000187:drug effects / Q000469:parasitology / Q000473:pathology; D016867:Immunocompromised Host; D008168:Lung / Q000187:drug effects / Q000382:microbiology / Q000473:pathology; D009285:Naphthoquinones / Q000627:therapeutic use*; D011010:Pneumocystis / Q000472:pathogenicity; D011020:Pneumonia, Pneumocystis / Q000150:complications / Q000188:drug therapy* / Q000517:prevention & control; D011355:Prodrugs / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley
D002219:Carbamates; D009285:Naphthoquinones; D011355:Prodrugs; C097447:atovaquone prodrug 17C91; D003907:Dexamethasone